| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41575-020-00378-1 |
| P698 | PubMed publication ID | 33219355 |
| P50 | author | Alberto Caminero | Q92682335 |
| Maria Ines Pinto-Sanchez | Q38641226 | ||
| Jason Tye-din | Q43120880 | ||
| Katri Lindfors | Q88982962 | ||
| P2093 | author name string | Daniel A Leffler | |
| Laura Kivelä | |||
| P2860 | cites work | Refractory Celiac Disease | Q90416510 |
| Intestinal Barrier Function in Gluten-Related Disorders | Q90460272 | ||
| Editorial: a non-dietary treatment for coeliac disease-two steps forward, one step back? Authors' reply | Q90578339 | ||
| AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review | Q90714366 | ||
| Identification of a γc Receptor Antagonist That Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21 | Q90771782 | ||
| Taming autoimmunity: Translating antigen-specific approaches to induce immune tolerance | Q91079984 | ||
| B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2 | Q91286177 | ||
| Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4+ T cells | Q91313147 | ||
| Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study | Q91343935 | ||
| Mechanisms by which gut microorganisms influence food sensitivities | Q91436954 | ||
| Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease | Q91460267 | ||
| Microbial Biomarkers in Patients with Nonresponsive Celiac Disease | Q91604688 | ||
| Evidence that pathogenic transglutaminase 2 in celiac disease derives from enterocytes | Q92018028 | ||
| Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond | Q92088921 | ||
| Nutritional Deficiencies in Children with Celiac Disease Resulting from a Gluten-Free Diet: A Systematic Review | Q92129699 | ||
| Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten | Q92184181 | ||
| A Quantitative Assessment of Gluten Cross-contact in the School Environment for Children With Celiac Disease | Q92201959 | ||
| Early Probiotic Supplementation and the Risk of Celiac Disease in Children at Genetic Risk | Q92421443 | ||
| Detection of Gluten in Gluten-Free Labeled Restaurant Food: Analysis of Crowd-Sourced Data | Q92670619 | ||
| Effects of Lactobacillus plantarum and Lactobacillus paracasei on the Peripheral Immune Response in Children with Celiac Disease Autoimmunity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Q92701900 | ||
| European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders | Q92840395 | ||
| Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease | Q92924596 | ||
| Characterisation of clinical and immune reactivity to barley and rye ingestion in children with coeliac disease | Q92964658 | ||
| Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy | Q93001449 | ||
| Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study | Q93169370 | ||
| Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study | Q93169374 | ||
| Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis | Q93178816 | ||
| How to manage adult coeliac disease: perspective from the NHS England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease | Q94960101 | ||
| A food-grade enzyme preparation with modest gluten detoxification properties | Q21091194 | ||
| Where are we on worms? | Q22242718 | ||
| The Oslo definitions for coeliac disease and related terms | Q24601971 | ||
| Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions | Q27336477 | ||
| Identification of tissue transglutaminase as the autoantigen of celiac disease | Q28243044 | ||
| Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial | Q28742115 | ||
| Structural basis for gluten intolerance in celiac sprue | Q29620706 | ||
| Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication. | Q30373078 | ||
| A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease | Q33626963 | ||
| Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury. | Q33765990 | ||
| Redox regulation of transglutaminase 2 activity | Q34055808 | ||
| Small- bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease | Q34083093 | ||
| Patient perception of treatment burden is high in celiac disease compared with other common conditions | Q34156584 | ||
| Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease | Q34322283 | ||
| Introduction of gluten, HLA status, and the risk of celiac disease in children. | Q34441210 | ||
| BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity | Q34443779 | ||
| Psychological morbidity of celiac disease: A review of the literature | Q34474144 | ||
| Factors That Increase Risk of Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life | Q34544591 | ||
| The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study | Q34581861 | ||
| The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo | Q34614251 | ||
| Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease | Q34627207 | ||
| In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. | Q34636531 | ||
| A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge | Q34640687 | ||
| Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study | Q34645550 | ||
| The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders | Q34658294 | ||
| Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue | Q34660135 | ||
| Randomized feeding intervention in infants at high risk for celiac disease | Q34665095 | ||
| Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. | Q35655989 | ||
| Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. | Q35760432 | ||
| Novel avian single-chain fragment variable (scFv) targets dietary gluten and related natural grain prolamins, toxic entities of celiac disease | Q35857457 | ||
| Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study. | Q36174419 | ||
| Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice | Q36344875 | ||
| Regulation of the activities of the mammalian transglutaminase family of enzymes | Q36620140 | ||
| Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease | Q36675105 | ||
| Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease | Q37144602 | ||
| Probiotics and the Microbiome in Celiac Disease: A Randomised Controlled Trial. | Q37150557 | ||
| Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study | Q37210839 | ||
| Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study | Q37221509 | ||
| Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. | Q37275552 | ||
| Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. | Q37503549 | ||
| Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing | Q37617069 | ||
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| Transglutaminase as a therapeutic target for celiac disease | Q38269678 | ||
| Celiac Disease and Anorexia Nervosa: A Nationwide Study | Q38756452 | ||
| Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies | Q38785121 | ||
| Accumulation of Heavy Metals in People on a Gluten-Free Diet | Q38949423 | ||
| Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. | Q38956502 | ||
| Living gluten-free: adherence, knowledge, lifestyle adaptations and feelings towards a gluten-free diet. | Q39190604 | ||
| Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins | Q39747742 | ||
| Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. | Q40254093 | ||
| Unexpected role of surface transglutaminase type II in celiac disease | Q40351852 | ||
| Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity | Q40627090 | ||
| Expanding antigen-specific regulatory networks to treat autoimmunity | Q40787726 | ||
| Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens | Q40933700 | ||
| In vitro induction of regulatory T cells by anti-CD3 antibody in humans | Q41774667 | ||
| Oral enzyme therapy for celiac sprue | Q42212923 | ||
| Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting | Q42376135 | ||
| Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. | Q42482567 | ||
| Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides | Q42508921 | ||
| Can an increase in celiac disease be attributed to an increase in the gluten content of wheat as a consequence of wheat breeding? | Q43246606 | ||
| T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase | Q43682637 | ||
| Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. | Q44417399 | ||
| Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet | Q44489656 | ||
| Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials | Q45256460 | ||
| No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease | Q46323022 | ||
| Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease | Q46605448 | ||
| Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Contr | Q47389065 | ||
| AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease | Q47596605 | ||
| Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet | Q47867778 | ||
| Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease | Q47982815 | ||
| Outcome measures in coeliac disease trials: the Tampere recommendations. | Q50026308 | ||
| Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. | Q51449292 | ||
| Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. | Q52650025 | ||
| Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease. | Q53444099 | ||
| Bifidobacterium infantis NLS Super Strain Reduces the Expression of α-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients. | Q53572632 | ||
| Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. | Q55053101 | ||
| Limited availability and higher cost of gluten-free foods. | Q55054287 | ||
| A commensal Bifidobacterium longum strain improves gluten-related immunopathology in mice through expression of a serine protease inhibitor. | Q55262976 | ||
| Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-α and short-chain fatty acids | Q56379208 | ||
| The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation | Q57174271 | ||
| Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics | Q58006988 | ||
| Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies | Q59813523 | ||
| Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2 | Q64099175 | ||
| Gluten Free Wheat: Are We There? | Q64102468 | ||
| Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort | Q64238901 | ||
| Persistent Economic Burden of the Gluten Free Diet | Q64257599 | ||
| Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial | Q64261077 | ||
| A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease | Q79512572 | ||
| Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? | Q81728996 | ||
| Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism | Q88148576 | ||
| Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease | Q88660930 | ||
| Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease | Q89595607 | ||
| IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease | Q89686918 | ||
| E40, a novel microbial protease efficiently detoxifying gluten proteins, for the dietary management of gluten intolerance | Q90069005 | ||
| Targeting the MHC Ligandome by Use of TCR-Like Antibodies | Q90211977 | ||
| P921 | main subject | celiac disease | Q11088 |
| P577 | publication date | 2020-11-20 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | Current and emerging therapies for coeliac disease |
Search more.